Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
// Andrew K. Kwegyir-Afful 1, 2 , Senthilmurugan Ramalingam 1, 2 , Puranik Purushottamachar 1, 2 , Vidya P. Ramamurthy 1, 2 , Vincent C.O. Njar 1, 2, 3 1 Department of Pharmacology, University of Maryland School of Medicine, Baltimore, MD 21201-1559, USA 2 Center for Biomolecular Therapeutics, University of Maryland School of Medicine, Baltimore, MD 21201-1559, USA 3 Marlene Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201-1559, USA Correspondence to: Vincent C.O. Njar, e-mail: vnjar@som.umaryland.edu Keywords: prostate cancer, androgen receptors (AR/AR-V7), galeterone (gal), gal’s analog VNPT55, mechanisms of AR/AR-V7 degradation Received: June 16, 2015 Accepted: July 03, 2015 Published: July 14, 2015 ABSTRACT Galeterone (Gal) is a first-in-class multi-target oral small molecule that will soon enter pivotal phase III clinical trials in castration resistant prostate cancer (CRPC) patients. Gal disrupts androgen receptor (AR) signaling via inhibition of CYP17, AR antagonism and AR degradation. Resistance to current therapy is attributed to up-regulation of full-length AR (fAR), splice variants AR (AR-Vs) and AR mutations. The effects of gal and VNPT55 were analyzed on f-AR and AR-Vs (AR-V7/AR v567es ) in LNCaP, CWR22Rv1 and DU145 (transfected with AR-Vs) human PC cells in vitro and CRPC tumor xenografts. Galeterone/VNPT55 decreased fAR/AR-V7 mRNA levels and implicates Mdm2/CHIP enhanced ubiquitination of posttranslational modified receptors, targeting them for proteasomal degradation. Gal and VNPT55 also induced significant apoptosis in PC cells via increased Bax/Bcl2 ratio, cytochrome-c release with concomitant cleavage of caspase 3 and PARP. More importantly, gal and VNPT55 exhibited strong in vivo anti-CRPC activities, with no apparent host toxicities. This study demonstrate that gal and VNPT55 utilize cell-based mechanisms to deplete both fAR and AR-Vs. Importantly, the preclinical activity profiles, including profound apoptotic induction and inhibition of CRPC xenografts suggest that these agents offer considerable promise as new therapeutics for patients with CRPC and those resistant to current therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710 · cited 1×
“This data is in contrast to a recent study where no AR-V7-positive patient had any appreciable clinical benefit from enzalutamide or abiraterone therapy [6], which clearly differentiates gal from these related aforementioned androgen/AR targeting drugs.”
ResultMolecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278 · cited 4×
“Overexpression of fAR and AR-Vs is implicated in resistance to current approved therapy in HSPC and CRPC [11, 12].”
BackgroundInfluentialHu, R., Dunn, T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., Partin, A. W., Vessella, R. L., Isaacs, W. B., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2764 · Cited by 1,077
Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
Sun, S., Sprenger, C. C. T., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41824 · Cited by 748 · cited 2×
“Interestingly ARv567es, which enhances fAR transcriptional activity [13, 36, 37] in metastatic CRPC is also degraded by gal and VNPT55.”
BackgroundResultEskes, R., Antonsson, B., Osen-Sand, A., Montessuit, S., Richter, C., Sadoul, R., Mazzei, G., Nichols, A., & Martinou, J.-C. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.1.217 · Cited by 651
Watson, P. A., Chen, Y. F., Balbas, M. D., Wongvipat, J., Socci, N. D., Viale, A., Kim, K., & Sawyers, C. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012443107 · Cited by 639 · cited 1×
“, AR3) reportedly increases transcription of AR target genes in PC cells [13, 15–18].”
BackgroundAkt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor.
Lin, H.-K., Yeh, S., Kang, H.-Y., & Chang, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121173298 · Cited by 401
Agoulnik, I. U., Bingman, W. E., Nakka, M., Li, W., Wang, Q., Liu, X. S., Brown, M., & Nancy L., N. L. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0481 · Cited by 36
Cited by
Role of Androgen Receptor in Prostate Cancer: A Review
Fujita, K., & Nonomura, N. (2019) · The World Journal of Men's Health · doi:10.5534/wjmh.180040 · Cited by 483
“Deregulation of the FHL2-filamin complex promotes constitutive, ligand-independent activation of AR variants such as ARV7 [41].”
BackgroundInfluentialCellular plasticity and the neuroendocrine phenotype in prostate cancer
Davies, A. H., Beltran, H., & Zoubeidi, A. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.22 · Cited by 431
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y.-T., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 261
The metabolism, analysis, and targeting of steroid hormones in breast and prostate cancer
Capper, C. P., Rae, J. M., & Auchus, R. J. (2016) · Hormones and Cancer · doi:10.1007/s12672-016-0259-0 · Cited by 89
“representing a novel antiandrogen mechanism of action [105].”
Background
Metadata
- Authors
- Kwegyir-Afful, A. K., Ramalingam, S., Purushottamachar, P., Ramamurthy, V. P., & Njar, V. C. O.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-07-14
- Volume
- 6
- Issue
- 29
- Pages
- 27440-27460
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1963137324
- Cited by
- 98
- References
- 9
- FWCI
- 13.56
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.